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Differences in allergen-induced T cell activation
between allergic asthma and rhinitis: Role of
CD28, ICOS and CTLA-4
Karine Botturi1,2,3*, Yannick Lacoeuille1,2, Arnaud Cavaillès1,2,3, Daniel Vervloet4, Antoine Magnan1,2,3
Abstract
Background: Th2 cell activation and T regulatory cell (Treg) deficiency are key features of allergy. This applies for
asthma and rhinitis. However with a same atopic background, some patients will develop rhinitis and asthma,
whereas others will display rhinitis only. Co-receptors are pivotal in determining the type of T cell activation, but
their role in allergic asthma and rhinitis has not been explored. Our objective was to assess whether allergen-
induced T cell activation differs from allergic rhinitis to allergic rhinitis with asthma, and explore the role of ICOS,
CD28 and CTLA-4.
Methods: T cell co-receptor and cytokine expressions were assessed by flow cytometry in PBMC from 18 house
dust mite (HDM) allergic rhinitics (R), 18 HDM allergic rhinitics and asthmatics (AR), 13 non allergic asthmatics (A)
and 20 controls, with or without anti-co-receptors antibodies.
Results: In asthmatics (A+AR), a constitutive decrease of CTLA-4+ and of CD4+CD25+Foxp3+ cells was found, with
an increase of IFN-g+ cells. In allergic subjects (R + AR), allergen stimulation induced CD28 together with IL-4 and
IL-13, and decreased the proportion of CTLA-4+, IL-10+ and CD4+CD25+Foxp3+ cells. Anti-ICOS and anti-CD28
antibodies blocked allergen-induced IL-4 and IL-13. IL-13 production also involved CTLA-4.
Conclusions: T cell activation differs between allergic rhinitis and asthma. In asthma, a constitutive, co-receptor
independent, Th1 activation and Treg deficiency is found. In allergic rhinitis, an allergen-induced Treg cell
deficiency is seen, as well as an ICOS-, CD28- and CTLA-4-dependent Th2 activation. Allergic asthmatics display
both characteristics.
Background
Atopic diseases including allergic rhinitis and asthma are
inflammatory conditions that have increased in preva-
lence over the past two decades [1]. The inflammatory
response to common environmental allergens during
allergy and asthma has been extensively studied in the
past years, and has clearly determined the pivotal role of
T cell activation, with a predominant Th2 cytokine pro-
duction [2,3]. T regulatory (Treg) cells, characterized by
the production of anti-inflammatory cytokines such as
IL-10 and TGF-b [4,5] are considered as responsible for
the normal tolerance against auto-antigens and external
antigens such as allergens [6]. Accordingly, a deficiency
in Treg counts and activation was found in autoimmune
diseases and allergic conditions, notably during allergen
exposure [7,8] and exacerbations of severe asthma [9].
However although this Th2/Treg imbalance applies both
for allergic rhinitis and asthma, it is remarkable that
despite a same atopic background and allergen expo-
sure, some subjects will develop both rhinitis and
asthma whereas other will display rhinitis only. We
hypothesize since several years that T cell activation is
different between both conditions and with others we
previously described a Th1 activation in asthma that
was absent in non asthmatic allergy in blood, induced
sputum and broncho-alveolar lavages [10-12]. However,
the role of allergen in the tuning of T cell activation in
allergic rhinitics with and without asthma was not
explored yet.* Correspondence: botturikarine@yahoo.fr1INSERM UMR915, Nantes, F-44000 France
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Allergen-induced T cell activation depends on signals
delivered from antigen presenting cells (APCs) through
the antigen-specific T cell receptor as well as additional
co-stimulatory signals provided by engagement of so-
called co-receptors on APCs and T cells [13]. Major T
cell co-receptors are CD28, inducible costimulatory
molecule (ICOS) and cytotoxic T lymphocyte antigen
(CTLA)-4. They belong to the immunoglobulin gene
superfamily and display various kinetics of expression.
CD28 is a constitutive co-stimulatory receptor binding
CD80 and CD86 on APCs, delivering important signals
for T cell activation and survival. Ligation of CD28 pro-
motes the production of IL-4 and IL-5 and provides
resistance to apoptosis and long-term expansion of
T-cells. As CD28, ICOS is a positive regulator of T cell
activation which is up-regulated on activated T-cells.
ICOS was initially shown to selectively induce high
levels of IL-10 and IL-4, but is also able to stimulate
both Th1 and Th2 cytokine production in vivo [14].
CTLA-4 is also a CD80/CD86-binding protein. It is
up-regulated on activated T cells and delivers mainly an
inhibitory signal, playing an important role in mainte-
nance of peripheral tolerance [15]. Indeed, it was shown
in murine Treg cells, that CTLA-4 controlled homeosta-
sis and suppressive capacity of regulatory T cells [16].
Co-receptors thus represent important potential tar-
gets for therapeutic immunomodulation. Indeed the
blockade of CD28 and CTLA-4 agonists are tested for
their ability to prevent graft rejection [17], and in animal
models, ICOS inhibition prevented allergic inflammation
[18]. However, the actual role of co-receptors in the
context of asthma and allergy in humans is still
unexplored.
The objective of this study was therefore to compare
the pattern of T cell activation between allergic rhinitics
and asthmatics upon allergen stimulation and to assess
the role of co-receptors CD28, ICOS and CTLA-4 in
this process.
Methods
Study population
Four groups of patients were recruited: allergic rhini-
tics (R), allergic rhinitics and asthmatics (AR), non
allergic asthmatics (A), and controls (C). All allergic
patients were selected to display house dust mite
(HDM) allergy. As rBetv1 birch pollen allergen was
used as control antigen for in vitro stimulation of T
cells, patients were selected to be not sensitized to
birch pollen. The diagnosis of HDM allergy was deter-
mined by positive skin prick test to Dermatophagoides
pteronyssinus extract (Stallergenes, France). Allergic
rhinitis was defined by the presence of perennial nasal
symptoms out of viral infection such as nasal obstruc-
tion, sneezing, rhinorrhea and nasal pruritus. The
diagnosis of asthma was done on the basis of a history
of dyspnea and wheezes with a reversible obstructive
ventilatory defect or a positive methacholine challenge.
The distinction between mild and moderate asthma
was done according to GINA classification [19]. In
patients, any inhaled corticosteroids and anti-hista-
mines were discontinued 15 days before sampling. As
controls, healthy non smoker individuals with normal
lung function, negative methacholine challenge and
negative skin prick test were included. In controls,
absence of allergy was established by the negativity of
35 skin prick tests to common environmental aeroal-
lergens, and absence of asthma was stated on negative
methacholine challenge and induced sputum eosino-
phil count below 3% (see additional file 1: Skin testing,
methacholine challenge and induced sputum proce-
dures). The positive methacholine test was defined by
a drop of at least 20% of FEV1(forced expiratory
volume in 1 second) in response to 200 μg or less of
metacholine. This project was approved by the local
Ethic Committee and written informed consent was
obtained from each patient.
Isolation of PBMC
Peripheral blood mononuclear cells (PBMC) were iso-
lated from peripheral venous blood by Ficoll-Hypaque
plus (GE Healthcare, Uppsala, Sweden) density gradient
centrifugation. Cells were then washed three times and
resuspended in complete medium RPMI-1640 supple-
mented with 10% (v/v) foetal calf serum (FCS), 2 mM
L-glutamine, 1 mM sodium pyruvate, 1 μM 2-mercapto-
ethanol (Sigma Chemical, Saint-Louis, Missouri), 1000
U/ml Penicillin and Streptomycin. All culture reagents,
except 2-mercapto-ethanol, were purchased from
GIBCO®.
Antigens
Recombinant (r) Betv 1 of birch pollen (Betula verru-
cosa) and purified (p) Derp 1 of house dust mite
(Dermatophagoides pteronyssinus) were provided by
Stallergènes (Antony, France). None of the allergens
contained detectable amounts of LPS.
Specific stimulation of T cells
Optimal dose of stimulatory pDerp1 and kinetics of T
cell cytokine secretion and proliferation were deter-
mined in an independent pilot study on 5 house dust
mite allergics and 5 healthy volunteers.
PBMC (5 × 105) were cultured in 96 wells plates (Fal-
con) in 100 μl medium containing 1 μg/ml pDerp1 at
37°C in 5%CO2 and cells were harvested after 8 days
culture. 50 μl of fresh complete medium was added
every 2 days in each well. rBetv1 was used as control
antigen at a concentration of 1 μg/ml.
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Surface staining
After 8 days of culture with pDerp 1, PBMC (5 × 105)
were harvested and stained with anti-CD4-PE-Cy5, anti-
CD25-FITC, (Beckman Coulter, Marseille, France); anti-
CD3-FITC (Dako, Trappes, France), anti-CD3-PE-Cy5
(Immunotools, Friesoythe, Germany), anti-CD28-FITC,
anti-ICOS-PE, or anti-CTLA-4-PE-Cy5 (BD Pharmin-
gen, le Pont de Claix, France) mAbs at recommended
concentrations. To detect Foxp3 intracellular transcrip-
tion factor, T cells were then fixed, permeabilized, and
stained with anti-Foxp3-PE mAb (eBiosciences, San
Diego, California). The Treg population was identified
as CD4+CD25Hi+Fox p 3+ cells.
Fluorescence was detected with a 15 mW argon ion
laser on a three colors FACSCan® (Becton Dickinson,
Franklin Lakes, NJ, USA). Standard acquisition and ana-
lysis software were obtained through Cellquest® Soft-
ware (Becton Dickinson).
Intracellular T cell cytokine staining
PBMC (5 × 105) were cultured for 8 days with pDerp 1.
PMA (Sigma Chemical, Saint-Louis, Missouri, 50 ng/
ml), Ionomycin (Euromedex, 2 μg/ml) and Monensin
(Sigma Chemical, 2 μM) were added during the last
6 hours of culture. These culture conditions allow the
detection of cytokines already engaged in a synthesis
process in vivo [20]. Cells were harvested and stained
with CD3-PE-Cy5 (Immunotools, Friesoythe, Germany).
Cells were then fixed, permeabilized, and stained with
antibodies to detect intracellular cytokines (anti-IFNg-
FITC, anti-IL-4-FITC, BD Pharmingen, le Pont de Claix,
France; anti-IL13-PE, anti-IL-10-PE, R&D system, Lille,
France). IL-4+ and IL-13+ cells were considered as Th2
cells, IFN-g + cells as Th1 cells. IL-10+ cells were con-
sidered as belonging to Treg cell population.
Co-receptor study
To determine the role of co-receptors in T cell activa-
tion, PBMC cultures were performed with or without
anti-CTLA-4 (clone 14D3, 12 μg/ml), anti-ICOS (clone
ISA-3, 12 μg/ml) or anti-CD28 (clone CD28.6, 3 μg/ml)
monoclonal antibodies (mAb). These mAb were pur-
chased from eBioscience.
Statistical Analysis
Analysis was performed using the Statview® Software.
Normal distributions of the variables were checked with
a Kolmogorov-Smirnof’s test. Average percentages of
positive cells and cytokine concentrations were then
compared between groups (controls, non allergic asth-
matics, allergic rhinitics and allergic asthmatics) using
the analysis of variance (ANOVA). When the ANOVA
showed statistical difference between groups, a multiple
linear regression analysis was done to identify if allergy,
asthma, or both could explain the variable studied.
Between-groups comparisons were performed using a
Student’s t-test. A paired t test was used to compare dif-
ferences between paired groups. A p value < 0.05 was
considered as statistically significant for all statistical
tests. Results are expressed as mean ± standard error
(SE).
Results
Study population
Sixty-nine subjects (33 males, 36 females, mean age
37.20 ± 1.90) were included. Blood samples from 20
healthy individuals with no history of allergy or asthma,
18 allergic asthmatics (AR), 18 allergic rhinitics (R), and
13 non allergic asthmatics (A) were collected. Character-
istics of the patients are shown in table 1.
None of the subjects was a smoker. Patients inter-
rupted their local or systemic steroids or antihistamines
15 days before sampling. Asthmatics were mild asth-
matics for one half and moderate asthmatics for the
other half. All allergic patients displayed symptoms
compatible with allergic rhinitis. All non allergic asth-
matics also complained from nasal symptoms. Healthy
volunteers did not report any symptom.
Sputum eosinophil counts were significantly higher in
asthmatics than in control subjects or allergic rhinitis,
with no significant difference between allergic and non
allergic asthmatics. None of the subjects was sensitized
to birch. The age difference between the A+R group
and other groups (A, R and C) was not significant
statistically.
T cell activation and co-receptor expression before
specific stimulation
Treg cells proportion, Th1 and Th2 cytokines produc-
tion and co-receptors expression (CTLA-4, ICOS,
CD28) in each group were first assessed by flow cytome-
try, prior to any specific stimulation.
In non-stimulated conditions, CTLA-4+ T cells were
decreased in asthmatics (p < 0.05 vs controls, figure
1A), whatever their allergic status. In keeping with this
result, a reduced Treg population (p < 0.025, figure 1B)
was found in these patients. Relevantly, Treg cell pro-
portions were higher in mild asthmatics than in moder-
ate counterparts (p < 0.012, figure 1C). IFN-g + cells
were increased (p < 0.022 vs controls, figure 1D) in
asthmatics. No significant difference in Th2 cytokines or
IL-10 production was found (table 2) between groups.
ICOS expression was higher in R compared to con-
trols (p = 0.029, figure 1E), but similar in AR and con-
trols. No significant variation was found at the level of
CD28 expression between groups (table 2).
The multiple linear regression analysis showed that
asthma (A + AR) was associated to lower ICOS and
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CTLA-4 expression and Treg cell proportions, but to
higher IFN-g+ T cells (table 3). By contrast, allergic rhi-
nitis (with or without asthma) was positively linked to
ICOS expression.
T cell activation and co-receptor expression after specific
stimulation by allergens
PBMCs were cultured in the presence or not of pDerp1
during 8 days. T cell activation and co-receptors expres-
sion were then studied by flow cytometry.
In AR, Der p 1 up-regulated CD28 (89.78 ± 1.33 vs
91.01 ± 1.48; p = 0.0016) and ICOS expression, and
decreased CTLA-4 (figure 2A). Furthermore, Derp1 sti-
mulation induced an increase in IL-4+ and IL-13+ cells
(figure 2A), without significant variation in IFN-g+ cells
(not shown). This increase in Th2 cells was associated
to a decrease in IL-10+ cells and Treg cells (figure 2A).
In R, Derp1 also increased CD28 (89.03 ± 1.71 vs
91.00 ± 1.48; p = 0.0025) but not ICOS expression
(figure 2B). It decreased CTLA-4+ cell proportions.
Table 1 Characteristics of the patients
Controls (n = 20) R (n = 18) AR (n = 18) A (n = 13)
Clinical Data
Gender, (M/F) 5/15 12/6 10/8 6/7
Age* 32.38 ± 4.49 33.68 ± 3.23 40.56 ± 3.59 50.61 ± 4.36
Body Mass Index 24 ± 0.5 22.5 ± 1.5 25 ± 4 24.5 ± 2
mild/moderate asthma - - 9/9 6/7
Lung function
FEV1, (% of theoretical value*) 100 ± 2.26 97.4 ± 4.30 89.5 ± 3.91 83.8 ± 6.64
Sputum eosinophils (%)* 0.5 ± 0.31 0.75 ± 0.75 14.78 ± 5.98** 29 ± 9.99**
FEV1 = Forced expiratory volume in 1 second.
*Values are mean ± standard error (SE),
**= p < 0.01. R = allergic rhinitis; A R = allergic asthma and rhinitis; A = non allergic asthmatics.
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Figure 1 T cell activation and co-receptor expression before specific stimulation. CTLA-4 expression (A), Treg cells (CD4+CD25+HiFoxp3+,
B), IFN-g producing T cells (D) and ICOS expression (E) were assessed by flow cytometry in PBMC from HDM allergic rhinitics (R) (triangle, n =
18), allergic asthmatics and rhinitics (AR) (square, n = 18), non allergic asthmatics (A) (lozenge, n = 13), and controls (circle, n = 20). Treg cells
were also evaluated in non allergic asthma and allergic asthma between mild and moderate asthmatics (C). Results are expressed as percentage
of total T cell and compared versus controls. _ : mean of each group. * = p < 0.05; ** = p < 0.01.
Botturi et al. Respiratory Research 2011, 12:25
http://respiratory-research.com/content/12/1/25
Page 4 of 10
Allergen stimulation induced an increase in Th2 cells
without variation of IFN-g + cells (not shown), and a
decrease in IL10+ and Treg cells (figure 2B).
Therefore at the exception of ICOS, that was already
increased at baseline in R and thus could not increase
upon stimulation, the profile of T cell activation and co-
receptor expression induced by Derp1 was similar in AR
and R subjects.
After specific stimulation (figure 2C-D), T cells from
asthmatic and non asthmatic allergics displayed higher
expression of ICOS (p < 0.02) and lower expression of
CTLA-4 compared to controls (p < 0.007). In addition
Th2 cell proportions were higher in allergics whereas
Treg cells were decreased (IL-4, p < 0.0022; IL-13, p <
0.0001; Treg, p < 0.008). CD28+ cell percentages were
not different between groups after allergen-specific sti-
mulation (not shown). In non allergic subjects (figure
2C-D) no significant variation was found in any of the
parameters studied
The multiple linear regression analysis showed that
after Derp 1 specific stimulation, allergy (R + AR) corre-
lated positively with percentages of ICOS, IL-13 and
IL-4-expressing T cells and negatively with CTLA-4 and
IL-10-expressing T cells (table 3).
No variation was found in any subject for any co-
receptor or cytokine expression after stimulation with
irrelevant rBetv1 (not shown).
Role of co-receptor engagement
In order to study the respective role of CD28, ICOS and
CTLA-4 in T cell activation patterns in the context of
allergen presentation, PBMC were stimulated with
Derp1 in the absence or presence of anti-ICOS, anti-
CTLA-4 or anti-CD28 mAb.
In allergics, whatever the asthmatic status (R + AR),
anti-ICOS and anti-CD28 mAb specifically decreased
IL-4+ and IL-13+ cells (figure 3A and table 4), but had
no influence on IFN-g+ cells (table 4). Anti-CTLA-4
mAb had no effect on IL-4+ cells, but unexpectedly
decreased IL-13+ cell proportions (table 4).
In non allergic subjects (A + controls), anti-co-recep-
tor antibodies did not affect Th1 or Th2 cytokine pro-
duction (figure 3 and table 4).
Discussion
The results of our ex vivo study strongly suggest a con-
trasted picture of T cell activation in allergic rhinitis
and asthma, with distinct patterns of Th1, Th2 and
Treg profiles and expression of ICOS, CD28 and CTLA-
4 co-receptors.
Indeed, we showed that in asthma, IFN-g production
was constitutive, did not increase upon allergen stimula-
tion, and was not blocked by any of the anti-co-receptor
antibodies. Similarly, the constitutive defect of Treg and
CTLA-4 expression seen in asthmatics and not
enhanced in non allergic asthmatics after allergen stimu-
lation was not modified after co-receptors blockade. The
Th1/Treg imbalance in asthma is therefore constitutive
and independent of allergen presentation.
The constitutive Th1 activation in asthma was
demonstrated before [10,12,21]. It could result from the
intrinsic defect in the CTLA-4+ and Treg populations
as CTLA-4, known to be involved in tolerance induc-
tion [22], could prevent the asthmatic inflammation by
Table 2 Baseline T-cell co-receptor and cytokine expression
Controls (n = 20) R (n = 18) AR (n = 18) A (n = 13)
CD3+IL-4+ (%) 2.38 ± 0.26 2.88 ± 0.29 2.35 ± 0.22 3.25 ± 0.60
CD3+IL-13+ (%) 3.02 ± 0.31 4.17 ± 0.48 3.54 ± 0.34 4.18 ± 0.54
CD3+IL-10+ (%) 5.01 ± 0.47 4.06 ± 0.33 4.38 ± 0.37 4.37 ± 0.46
CD3+CD28+ (%) 87.75 ± 2.50 89.04 ± 1.71 89.50 ± 1.31 84.85 ± 3.45
PBMC from each patient were cultured in complete medium during 8 days. ICOS, CD28, IL-4, IL-13, and IL-10 expression by T-cells were assessed by flow
cytometry. Results are expressed as mean of total T-cells ± SE and compared versus controls. * = p < 0.05, ** = p < 0,01. R = allergic rhinitis; A R = allergic
asthma and rhinitis; A = non allergic asthmatics.
Table 3 Multiple linear regression analysis between asthma, allergy and allergy after specific stimulation
Asthma (A+AR) Allergy (R+AR) Allergy + specific stimulation (R+AR+Derp1 stimulation)
CD3+ICOS+ (%) -1.502 ± 0.75 (p = 0.0485) 1.675 ± 0.75 (p = 0.0292) 2.929 ± 0.81 (p = 0.0006)
CD3+CTLA-4+ (%) -1.649 ± 0.61 (p = 0.0087) 0.508 ± 0.61 (p = 0.4088) -1.406 ± 0.60 (p = 0.0223)
CD3+IL-4+ (%) 0.188 ± 0.34 (p = 0.585) -0.066 ± 0.34 (p = 0.848) 1.12 ± 0.37 (p = 0.034)
CD3+IL-13+ (%) 0.287 ± 0.43 (p = 0.508) 0.429 ± 0.43 (p = 0.325) 2.209 ± 0.43 (p < 0.0001)
CD3+IFN-g+ (%) 3.3643 ± 1.63 (p = 0.0283) 1.44 ± 1.62 (p = 0.378) 0.884 ± 1.42 (p = 0.535)
CD4+CD25Hi+Foxp3+ (%) -1.647 ± 0.54 (p = 0.0033) -0.371 ± 0.54 (p = 0.494) -0.774 ± 0.52 (p = 0.142)
CD3+IL-10+ (%) -0.146 ± 0.42 (p = 0.729) -0.549 ± 0.42 (p = 0.196) -1.896 ± 0.44 (p < 0.0001)
Values are expressed as coefficient of regression ± SE.
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inducing T cells to differentiate in T regulatory cells.
Recently, we have showed during in vivo studies a lower
proportion of Treg cells in blood from severe refractory
asthmatics compared to controls, which was even dee-
per during exacerbations, both in blood and induced
sputum [9]. Herein we show that this lower proportion
of Treg is present in milder stages of asthma. Rele-
vantly, Treg cells were higher in mild than in moderate
asthma whatever the allergic status. This results are
concordant with the primary Treg cell deficiency sug-
gested in asthma and allergy [23]. That the Th1/Treg
imbalance is similar in allergic and non allergic asthma
suggests that it is a characteristic of asthma indepen-
dent of allergy, possibly triggered by infectious agents
or non specific substances such as pollutants but it
must be precised that asthmatics included in the pre-
sent study were controlled and did not experienced any
recent exacerbation. Another hypothesis would be that
the Th1/Treg imbalance in asthma is really intrinsic
and independent of any external aggression.
In allergic groups, we demonstrated a Th2/Treg
imbalance inducible upon allergen stimulation. That
Th2 activation was not seen in non allergic patients and
could be broken by CD28 and ICOS blockade indicates
that it is really the cognate allergen presentation by anti-
gen presenting cells that was responsible for it. IL-13
secretion was suppressed also by blocking CTLA-4, indi-
cating that in peripheral cells (1) Th2 activation cannot
be considered globally, Th2 cytokines being regulated
distinctly, and (2) CTLA-4 being not only involved in
tolerance but also in inflammation. This result is con-
cordant with Lordan and al., who showed that allergen-
induced production of IL-5 and IL-13 by PBMC from
allergic asthmatics could be inhibited by blocking
CTLA-4 receptor with CTLA-4-Ig [24]. Regarding the
allergen-induced Treg defect in allergics, other co-
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Botturi et al. Respiratory Research 2011, 12:25
http://respiratory-research.com/content/12/1/25
Page 6 of 10
receptors than these tested are likely involved, among
which PD1 is a candidate [25]. Indeed, Meiler et al.
recently demonstrated in PBMC from allergic patients
that the suppressive effect of IL-10 secreting T cells was
partially inhibited by blocking CTLA-4 or PD-1 co-
receptors, whereas blocking both receptors simulta-
neously had an additive effect [26].
The association of allergy with ICOS over-expression
before any allergen stimulation suggests a non specific
priming of T cells towards the Th2 pathway in allergic
subjects. Indeed ICOS was clearly related to Th2 activa-
tion, as shown by anti-ICOS stimulation results. Numer-
ous studies using animal models of airways inflammation
have showed that ICOS-mediated signalling was essential
for induction of Th2 cytokines [27,28]. Indeed inhibition
of ICOS suppresses allergic lung inflammation and Th2
cytokines production in mice models [29]. However in
other models ICOS engagement induces tolerance and
inhibits the allergic inflammation. These distinct actions
of ICOS seem related to the density of ICOS molecules
per cell, with inflammation being related to a high den-
sity of co-receptors and tolerance induction to a lower
number of ICOS molecules per cell [30].
That in R ICOS expression does not increase after
allergen stimulation by contrast with the AR group
could result from a maximal expression of ICOS in R
whereas it is still inducible in AR. Indeed the basal level
of ICOS expression is lower in the latter group than in
the former. This relative defect in ICOS expression in
AR patients could result from the constitutive Th1/Treg
imbalance of asthmatics that by a Th1-driven “anti-Th2”
effect would decrease ICOS expression.
Under allergen stimulation, CD28 expression
increased significantly in R and AR, and blockade of
CD28 decreased the Th2 cytokine production, indicating
the involvement of CD28 in Th2 cell activation in
allergy. It is noteworthy that although significant statisti-
cally, the proportion of CD28+ cells could not increase
in high proportion, as most T cells constitutively
expressed CD28 in all groups. CD28 is a crucial co-
receptor for inducing T cell cytokine production [31],
and was showed to be involved both in Th1 and Th2
activation. CD28 blockade is proposed as an immuno-
suppressive strategy to prevent graft rejection, and is
experimented in various inflammatory diseases. However
the practical use of CD28 blockade was refrained by the
agonist action of some anti-CD28 antibodies encoun-
tered in clinical trials [32].
Our study provides new insights into the hypothesis of
Treg cell deficiency as a paradigm for allergic diseases,
by showing a constitutive Treg cell deficit in asthma
whatever the allergic status and an inducible Treg deficit
in allergy, whatever the presence of asthma. As a conse-
quence, the Treg cell deficiency is the highest in asth-
matic allergics after allergen stimulation. This
distinction between allergy and asthma contradicts our
previous hypothesis of a gradient of Treg cell deficiency
from allergy to asthma [23], and better suggests that the
abnormalities seen in both diseases could be juxtaposed
and independent, as showed by the multiple linear
regression analysis.
Recently an in vivo study showed no difference in the
number of Treg cells between asthmatics and controls,
whereas FOXP3 protein expression within Treg cells
was significantly decreased in asthmatic patients [33].
Our study was performed in blood ex vivo and therefore
might not fully reflect the in vivo and in situ reality.
However many studies showed that blood compartment
was relevant to the in situ inflammation as far as T cells
and allergy were concerned [21], and the mechanistic
studies proposed here cannot be assessed in situ in
humans. They can be performed in vivo in animals, but
the relevance to real asthma would also be uncertain.
In conclusion, allergy is associated to a constitutive
ICOS over-expression and inducible CTLA-4 under-
expression with Th2/Treg imbalance, when a constitu-
tive CTLA-4 under-expression and Th1/Treg disequili-
brium appears as a hallmark of asthma. Both profiles
are mixed in allergic asthma, and one can argue that
asthma would occur in allergic subjects only if the
unknown conditions leading to the constitutive Th1
activation are present. Still missing in the puzzle is the
stimulus inducing the Th2 activation present in non
allergic asthma [3]. Lastly, our results demonstrate that
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Figure 3 Effect of anti-co-receptors antibodies on IL-13
production by T cells. PBMC from allergic rhinitics (R) (triangle, n =
12), allergic rhinitic and asthmatics (AR) (square, n = 10) and non
allergic asthmatics (A) (lozenge, n = 11) were stimulated with Derp
1 and cultured in the presence or absence of anti-ICOS, anti-CTLA-4
or anti-CD28 antibodies. IL-13 expressing T cells were then
compared in each group versus baseline. Results are expressed as
percentage of total T cells. Black line : mean of each group. * = p <
0.05; ** = p < 0.01; *** = p < 0.001.
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Table 4 Effect of anti-co-receptors antibodies on Treg cells, IL-10 and IFN-g production
R (n = 12) AR (n = 10) A (n = 11)
Derp1 Derp1+
anti-ICOS
Derp1+ anti-
CTLA4
Derp1+
anti-CD28
Derp1 Derp1+ anti-
ICOS
Derp1+
anti-CTLA4
Derp1+
anti-CD28
Derp1 Derp1+
anti-ICOS
Derp1+ anti-
CTLA4
Derp1+
anti-CD28
CD3+IL-10+(%) 3.82 ± 0.49 3.79 ± 0.30 4.66 ± 1.05 3.31 ± 0.32 3.80 ± 0.41 3.54 ± 0.46 3.96 ± 0.50 3.60 ± 0.52 5.03 ± 0.68 4.42 ± 0.56 4.42 ± 0.64 4.37 ± 0.64
CD4+CD25Hi+
Foxp3+ (%)
4.25 ± 0.45 4.49 ± 0.65 4.24 ± 0.57 3.57 ± 0.65 3.61 ± 0.70 4.21 ± 1.13 3.87 ± 0.83 2.78 ± 0.83 2.65 ± 0.47 2.47 ± 0.38 2.55 ± 0.40 1.75 ± 0.29
CD3+IFN-g+ (%) 7.48 ± 1.15 6.13 ± 0.75 7.24 ± 1.11 7.63 ± 0.98 12.26 ± 1.35 11.86 ± 1.01 13.99 ± 1.84 13.64 ± 1.36 11.90 ± 1.89 10.43 ± 1.78 12.35 ± 1.74 12.32 ± 1.98
CD3+IL-4+ (%) 4.22 ± 0.55 2.01 ± 0.26* 3.67 ± 0.94 2.33 ± 0.40* 3.29 ± 0.49 2.21 ± 0.15*** 2.85 ± 0.34 2.41 ± 0.22** 3.53 ± 0.50 2.56 ± 0.54 2.92 ± 0.51 3.11 ± 0.95
PBMC from allergic non asthmatics (R, n = 12), allergic asthmatics (AR, n = 10) and non allergic asthmatics (A, n = 11), were stimulated with Derp 1 and cultured in the presence or absence of anti-ICOS, anti-CTLA4 or
anti-CD28 antibodies. Treg cells, IL-10 and IFN-g production by T-cells were assessed by flow cytometry. Results are expressed as mean of total T-cells ± SE and compared versus absence of anti-co-receptors
antibodies conditions. R = allergic rhinitis; A R = allergic asthma and rhinitis. * = p < 0.05, ** = p < 0,01, *** = p < 0,001.
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although targeting one type of T cell activation only
would be a pitfall in allergic asthma, there is a rationale
to develop strategies based on targeting co-receptors in
allergy.
Conclusion
In conclusion, our work adds significant insights into
the immune mechanism involved in allergy and asthma
and states the rationale for new diagnosis and/or thera-
peutic strategies in these pathologies.
Additional material
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sputum procedures.
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